Matching articles for "suzetrigine"
Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
The Medical Letter on Drugs and Therapeutics • March 3, 2025; (Issue 1723)
The FDA has approved suzetrigine (Journavx –
Vertex), a selective sodium channel blocker, for oral
treatment of moderate to severe acute pain in adults.
Suzetrigine is the first sodium channel blocker to...
The FDA has approved suzetrigine (Journavx –
Vertex), a selective sodium channel blocker, for oral
treatment of moderate to severe acute pain in adults.
Suzetrigine is the first sodium channel blocker to be
approved in the US for this indication and the first oral
nonopioid drug to be approved for treatment of pain
in over 25 years.